Latest Conference Articles

June 3rd 2018, 10:14pm

ASCO Annual Meeting

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

June 3rd 2018, 9:37pm

ASCO Annual Meeting

Sunitinib alone was noninferior to cytoreductive nephrectomy plus sunitinib, the current standard of care, in patients with synchronous metastatic renal cell carcinoma.

June 3rd 2018, 9:17pm

ASCO Annual Meeting

A course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy led to significant improvements in disease-free and overall survival in pediatric rhabdomyosarcoma.

June 3rd 2018, 7:35pm

ASCO Annual Meeting

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

June 3rd 2018, 5:11am

ASCO Annual Meeting

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

June 3rd 2018, 4:45am

ASCO Annual Meeting

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.

June 2nd 2018, 10:54pm

ASCO Annual Meeting

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

June 2nd 2018, 10:44pm

ASCO Annual Meeting

Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.

June 2nd 2018, 9:57pm

ASCO Annual Meeting

Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.

June 2nd 2018, 9:48pm

ASCO Annual Meeting

Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.

June 2nd 2018, 9:34pm

ASCO Annual Meeting

Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer

June 2nd 2018, 9:09pm

ASCO Annual Meeting

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.

June 2nd 2018, 8:55pm

ASCO Annual Meeting

The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.

June 2nd 2018, 8:22pm

ASCO Annual Meeting

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.

June 2nd 2018, 6:58pm

ASCO Annual Meeting

Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.

June 2nd 2018, 9:43am

ASCO Annual Meeting

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

June 2nd 2018, 5:24am

ASCO Annual Meeting

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses pooled findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

June 2nd 2018, 4:52am

ASCO Annual Meeting

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

June 2nd 2018, 4:22am

ASCO Annual Meeting

Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.

June 2nd 2018, 3:44am

ASCO Annual Meeting

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.